2017年，国际细胞学会宣布了针对乳腺细针穿刺活检（FNAB）的五级报告系统。我们观察到不足/不够的病例率在2.05%至39.89%之间变化，恶性风险变化率从0%至60.87%。这种广泛的变化范围可能会使很多患者面临管理延迟的风险。有些作者将即时评估（ROSE）描述为减少这种情况的工具。在这项初步审查中，我们还观察到没有统一指南可用于ROSE，以降低不足/不够类别的比率。我们期望细胞病理学家未来将构建一些ROSE的统一指南，这可能有助于减少一类的比率。©2023 Wiley Periodicals LLC.

In 2017, the International Academy of Cytology announced a five-tier reporting system for breast fine-needle aspiration biopsy (FNAB) cytopathology. We observed the insufficient/inadequate cases rate varied from 2.05% to 39.89%, with a risk of malignancy varying from 0% to 60.87%. This wide range of variation poses a significant number of patients at risk due to delay in management. Some authors describe rapid on-site evaluation (ROSE) as a tool to reduce its rate. In this preliminary review, we also observed that there were no uniform guidelines available for ROSE to reduce the insufficient/inadequate category rate. We expect that cytopathologists will construct some uniform guidelines for ROSE in the future, which may help to reduce the rate of category 1.© 2023 Wiley Periodicals LLC.